Persistence of primary drug resistance among recently HIV-1 infected adults

AIDS

Volumn 18, Issue 12, 2004, Pages 1683-1689

  Barbour, Jason D ^a,b   Hecht, Frederick M ^c   Wrin, Terri ^d   Liegler, Teri J ^a   Ramstead, Clarissa A ^c   Busch, Michael P ^c,e   Segal, Mark R ^b   Petropoulos, Christos J ^d   Grant, Robert M ^a,b  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MONOGRAM BIOSCIENCES   (United States)

^e Blood Centers of the Pacific   (United States)

Author keywords

Acute infection; Anti retroviral therapy; Drug resistance; HIV 1; Replication capacity; Surveillance; Viral evolution

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; POL PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE REPLICATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; STRUCTURAL GENE; T LYMPHOCYTE; VIRUS GENE;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; GENES, POL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRUS REPLICATION;

EID: 4143113433     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131391.91468.ff     Document Type: Article

References (33)

1. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CI, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288:181-188.
2. Little SJ, Holte S, Routy IP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
3. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354:729-733.
4. Wensing AMJ, van de Vijver DAMC, Asjo B, Balotta C, Camacho R, de Mendoza C, et al. Prevalence of transmitted drug resistance in europe is largely influenced by the presence of non-B sequences: analysis of 1400 patients from 16 countries: the CATCH-study. XII International HIV Drug Resistance Workshop. Los Cahos, B.C.S., Mexico, June 2003.
5. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999, 353:863-868.
6. Hirsch M, Steigbigel R, Staszewski S, Mellors I, Scerpella E, Hirschel B, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis 1999, 180:659-665.
7. Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002, 76:11104-11112.
8. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344:472-480.
9. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
10. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
11. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998, 72:3300-3306.
12. Goudsmit J, de Ronde A, de Rooij E, de Boer R. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol 1997, 71:4479-4484.
13. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999, 73:3744-3752.
14. Hecht FM, Grant RM, Petropoulos CI, Dillon B, Chesney MA, Tian H, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998, 339:307-311.
15. Ianssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998, 280:42-48.
16. Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, et al. Higher CD4+ T Cell Counts Associated with Low Viral pol Replication Capacity Among Treatment Naive Adults in Early HIV-1 Infection. J Infect Dis 2004, 190:251-256.
17. Grant RM, Kuritzkes DK, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, et al. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol 2003, 41:1586-1593.
18. Kuritzkes DR, Grant RM, Feorino P, Griswold M, Hoover M, Young R, et al. Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol 2003, 41:1594-1599.
19. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000, 44:920-928.
20. Parkin NT, Hellmann NS, Whitcomb IM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wildtype human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004, 48:437-443.
21. Littell R, Milliken G, Stroup G. SAS System for Mixed Models. Cary, NC: SAS Institute; 1996.
22. Diggle P, Liang, K., Zeger, S. Analysis of Longitudinal Data. Oxford: Oxford University Press; 1994.
23. Kothe D, Byers RH, Caudill SP, Satten GA, Janssen RS, Hannon WH, et al. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr 2003, 33: 625-634.
24. Larder BA. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992, 36:2664-2669.
25. Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 2002, 16:F41-F47.
26. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002, 76:1753-1761.
27. Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, Bates M, et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003, 37:1693-1698.
28. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003, 100:4144-4149.
29. Yu XG, Addo MM, Rosenberg ES, Rodriguez WR, Lee PK, Fitzpatrick CA, et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol 2002, 76:8690-8701.
30. Violin M, Cozzi-Lepri A, Velleca R, Vincenti A, D'Elia S, Chiodo F, et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 2004, 18:227-235
31. Gatanaga H, Suzuki Y, Tsang H, Yoshimura K, Kavlick MF, Nagashima K, et al. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem 2002, 277:5952-5961.
32. Huang W, Gamarnik A, Limoli K, Petropoulos CJ, Whitcomb JM. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol 2003, 77:1512-1523.
33. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996, 15:4040-4049.